Victoria, British Columbia, Canada, March 9, 2017 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF), a life sciences technology and product company engineering custom antibodies, is pleased to announce that David Kroeger, PhD. has joined the Company as Senior Scientist.
Dr. Kroeger will be working with ImmunoPrecise’s team of Principal Scientists, bringing with him a broad skillset in immunology, immuno-oncology, and antibody technology. Dr. Kroeger was recently awarded the Deeley Research Centre award for “outstanding contributions to cancer research on Vancouver Island” at the BC Cancer Agency.
Dr. Kroeger earned his PhD in immunology at the University of Saskatchewan in 2012 where he studied cellular interactions between B cells and T cells and their immunological outcomes. He did his postdoctoral training at the BC Cancer Agency’s Deeley Research Centre where he worked under Brad Nelson, Director and Distinguished Scientist. During his time at BC Cancer Agency, Dr. Kroeger studied the immune response to human cancer and made discoveries regarding the role of B cells in antitumor immunity. In addition to basic research, Dr. Kroeger made translational contributions including developing methods for cloning fully human antibodies from single tumor infiltrating B cells.
“We are delighted that Dr. Kroeger recently joined our team of Principal Scientists,” said Teri Otto, Director of Laboratory Services for ImmunoPrecise. “He has published multiple papers in the field of immuno-oncology and recently received a peer-nominated award for excellence in research at BC Cancer Agency. He adds valuable and relevant experience to our team. His background and experience will help us accelerate our business objectives”.
Dr. Kroeger added, “I’m excited to be working with the talented team at ImmunoPrecise. My time at BC Cancer Agency gave me the ideal background to lead scientific development and help ImmunoPrecise continue to be a leader in the in the custom antibody field.”
ImmunoPrecise also announces that it applied and received approval to change the trading symbol of the Company’s common stock in the United States. The Company also announces that it has approved a change of the trading symbol of the Company’s common stock in the United States. Effective immediately, the new OTC symbol for ImmunoPrecise will be “IPATF.” Information such as stock trading and market data, related to ImmunoPrecise Antibodies Ltd., will be reported under the new ticker symbol. The previous US trading symbol was “TQURF.”
ImmunoPrecise is a life sciences product and technology company engineering custom antibodies for the global research and industrial community. The Company uses proprietary innovative inoculation and cloning technologies and established expertise to produce monoclonal antibodies significantly faster than traditional methods of antibody production. Since its inception in 1989, it has used these capacities to produce hundreds of monoclonal antibodies now sold commercially through industry partners.
ImmunoPrecise is headquartered in Victoria, British Columbia and has its own in-house animal care unit, tissue culture facility and molecular facility. To learn more about ImmunoPrecise, please visit www.ipatherapeutics.com
For further information please contact:
ImmunoPrecise Antibodies Ltd.
Unit 3204 – 4464 Markham Street
Victoria, BC V8Z 7X8, Canada
For investor relations please contact:
Contact Financial Corp.
1450 – 701 West Georgia St.
Vancouver, BC V7Y 1G5
Forward Looking Information
This news release contains statements that, to the extent they are not recitations of historical fact, may constitute “forward-looking statements” within the meaning of applicable Canadian securities laws. ImmunoPrecise uses words such as “may”, “would”, “could”, “will”, “likely”, “expect”, “believe”, “intend” and similar expressions to identify forward-looking statements. Any such forward-looking statements are based on assumptions and analyses made by ImmunoPrecise in light of its experience and its perception of historical trends, current conditions and expected future developments. However, whether actual results and developments will conform to ImmunoPrecise’s expectations and predictions is subject to any number of risks, assumptions and uncertainties. Many factors could cause ImmunoPrecise’s actual results to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors include, among other things: risks and uncertainties described in the Company’s Filing Statement dated December 13, 2016 which can be accessed at www.sedar.com. The “forward-looking statements” contained herein speak only as of the date of this press release and, unless required by applicable law, the Company undertakes no obligation to publicly update or revise such information, whether as a result of new information, future events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.